IL-17A通过ACT1依赖的YAP-AREG轴激活促进银屑病相关角质形成细胞增殖
本研究探讨IL-17A是否通过调控Hippo-YAP信号通路促进角质形成细胞增殖。结果显示银屑病患者皮肤中YAP-AREG通路激活,且可被IL-17A拮抗剂司库奇尤单抗抑制;咪喹莫特和IL-17A可在小鼠表皮激活YAP-AREG轴。体外实验提示IL-17A通过激活Hippo-YAP信号增强AREG表达和角质形成细胞增殖,机制涉及IL-17A刺激MST1募集至ACT1,减少MST1-LATS1相互作用并导致YAP去磷酸化。
要点
- 银屑病患者皮肤中YAP-AREG通路激活,且可被司库奇尤单抗抑制。
- 咪喹莫特和IL-17A可在小鼠表皮激活YAP-AREG轴。
- IL-17A通过ACT1依赖机制激活YAP-AREG信号促进角质形成细胞增殖。
核心结论
- IL-17A通过激活YAP-AREG信号通路促进银屑病中角质形成细胞增殖,机制涉及MST1募集至ACT1、减少MST1-LATS1相互作用及YAP去磷酸化。
研究设计与样本
- 研究采用人银屑病皮肤标本、小鼠模型及体外HaCaT和正常人表皮角质形成细胞实验。
主要发现
- 人银屑病皮肤中YAP-AREG通路激活,且被IL-17A拮抗剂司库奇尤单抗抑制。
- 咪喹莫特和IL-17A处理可在小鼠表皮激活YAP-AREG轴。
- 体外实验显示IL-17A通过激活Hippo-YAP信号增强AREG表达和角质形成细胞增殖。
- 机制上IL-17A刺激MST1募集至ACT1,减少MST1-LATS1相互作用并导致YAP去磷酸化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Psoriasis is a recurrent inflammatory skin disorder characterized by epidermal hyperplasia, which is primarily driven by IL-17A. The Hippo-YAP signaling pathway plays a vital role in cell survival and tissue growth, and its target gene, AREG, has been reported to promote the development of psoriasis. However, whether IL-17A promotes keratinocyte proliferation through regulating Hippo-YAP signaling has not been explored. In this study, we show that the YAP-AREG pathway is activated in human psoriatic skin and is suppressed by IL-17A antagonist secukinumab and that imiquimod and IL-17A administration activates the YAP-AREG axis in mice epidermis. In vitro studies using HaCaT and normal human epidermal keratinocyte cells suggest that IL-17A enhances AREG expression and keratinocyte proliferation by activating Hippo-YAP signaling. Mechanistically, IL-17A stimulates the recruitment of MST1 to ACT1 in keratinocytes, which leads to reduced MST1-LATS1 interaction and YAP dephosphorylation. Together, our findings reveal a previously unknown mechanism in which IL-17A promotes keratinocyte proliferation in psoriasis, namely through activating YAP-AREG signaling.
引用
- Yu Z, Yu Q, Xu H, et al. IL-17A Promotes Psoriasis-Associated Keratinocyte Proliferation through ACT1-Dependent Activation of YAP-AREG Axis. J Invest Dermatol. 2022. PMID: 35304250. doi:10.1016/j.jid.2022.02.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。